We publish recommendations and resources, together with a host of other material for the benefit of our users.

A systematic approach to occupational risk assessment informs decisions about safe working practices with monoclonal antibodies (mAb)
A digest of NHS Specialist Pharmacy Service support for professionals working in all areas of the healthcare system for June 2025.
SPS PGD template for supply of doxycycline post exposure prophylaxis (doxyPEP) for the prevention of syphilis.
A digest of NHS Specialist Pharmacy Service support for professionals working in all areas of the healthcare system for May 2025.
A digest of NHS Specialist Pharmacy Service support for professionals working in all areas of the healthcare system for April 2025.
SPS PGD template for administering intravenous hyoscine butylbromide for imaging investigations by registered Radiographers.
A digest of NHS Specialist Pharmacy Service support for professionals working in all areas of the healthcare system for March 2025.
SPS PGD template for supply of cytisinicline to support smoking cessation in specified individuals.
SPS PGD template for administering gadopiclenol intravenously for imaging investigations and procedures by registered Radiographers.
A list of new product evaluations that are freely available to NHS staff.
Data exclusivity and market protection periods prevent generic or biosimilar competition for at least 10 years after the originator medicine is licensed.
Patents allow the inventor a finite period of monopoly in exchange for publicising the idea. We explain how they work with respect to medicines.
New medicines have several protections against competition. Other factors influence availability of generics or biosimilars after loss of exclusivity.
An update supporting system implementation of biosimilar and key generic medicines. 9 July 2025.
Cutting or masking transdermal patches is discouraged. Matrix patches can be cut if no licensed alternatives are available; reservoir patches should not be cut.
Guidance on adhesion, skin reactions, missing, omitted or delayed application, dosing intervals, switching, accidental exposure, and MRI scan considerations.
Practical guidance for safe application, monitoring, removal, disposal, documentation and storage of transdermal patches to reduce risk of medication errors.
Hydromorphone products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
A list of new product evaluations that are freely available to NHS staff.
A resource collating the latest medication safety communications and publications to inform, support and inspire medication safety improvements.
Know what medicines are in the pipeline. Understand the strategic and operational challenges for the NHS. Start planning early.
The Web Assistant will help you to answer questions about medicines in patients with swallowing difficulties.
E-learning developed by SPS in partnership with UKHSA, HEE and eLfH to support professionals who use, develop, authorise, review or update PGDs.
These are the detailed and easy read summary reports of the northern pharmacy technical services (PTS) workforce project. They provide a critical analysis of the…
SPS have developed a template audit tool to support organisations in auditing aspects of PGD development and use.
Advice on the use of Patient Group Directions (PGDs) to supply or administer a medication which is part of a clinical trial, study or pilot
This audit document is intended to be used to audit Pharmacy aspects of the safe administration of intrathecal chemotherapy, as part of the EL(97)52 Audit…